Loading...
Loading...
Shares of
Perrigo Company plcPRGO plunged more than 15 percent on Monday and hit a new 52-week low after the company appointed John T. Hendrickson as CEO and
provided preliminary first quarter results in addition to full year 2016 guidance.
Henrdickson was named as CEO following the retirement of Joseph Papa who accepted the CEO title at
Valeant Pharmaceuticals Intl IncVRX
Perrigo's first quarter preliminary guidance consisted of an earnings per share range of $1.71 to $1.77 on sales of $1.33 billion to $1.35 billion. Wall Street analysts were expecting the company to earn $1.89 per share on revenue of $1.4 billion.
Looking forward to the full fiscal year, Perrigo cut its earnings per share guidance range from $9.50 to $10.10 per share to a new range of $8.20 to $8.60 per share.
Perrigo's disappointing outlook resulted in a sell-off in other pharmaceutical names.
Shares of
Allergan plcAGN were trading lower by around 2 percent while shares of
lost around 1.50 percent.
Shares of both
Merck & Co., Inc.Loading...
Loading...
and
AbbVie IncABBV were lower by more than 1 percent each while
Pfizer Inc.PFE saw its shares shed around 0.60 percent
Loading...
Loading...
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in